Latest Content

Seventeen established and emerging eye care professionals from the United States and Canada were named as 2026 Visionaries.

The prospective observational study is being conducted across 18 countries.

The study included 144 patients with glaucoma or ocular hypertension who underwent 24-hour IOP monitoring between October 2023 and April 2024.

The lenses are commercially available in Canada as of February 2, 2026.

The goal of the study was to investigate the natural history of macular tissue preservation in GA by evaluating the relationship between the MTII and BCVA over time.

A total of 38 patients were included in the study. All underwent implantation of the PRIMA retinal prosthetic chip with the goal of restoring vision.

In this podcast, experts Charles C. Wykoff, MD, PhD, FASRS; Jed H. Assam, MD, MS; Diana V. Do, MD; and Dante Pieramici, MD, FASRS; discuss the diagnosis, clinical features, and evolving management strategies for patients diagnosed with macular telangiectasia type 2.

In this podcast, experts Janelle L. Davison, OD; Cecelia Koetting, OD, FAAO, DipABO; and Cory J. Lappin, OD, MS, FAAO; discuss neuromodulation as a treatment modality for dry eye disease, focusing on a novel thermoregulatory therapy.

In this podcast, expert Mile Brujic, OD, FAAO, discusses the burden, diagnosis, and management of Demodex blepharitis, highlighting a recently approved targeted treatment option.

This research is part of the IIH Research and Treatment Initiative, a new philanthropy-funded program launched at Mass General Brigham.

Formerly known as Brimochol PF, the dual-agent eye drop is now the first and only of its kind for the treatment of presbyopia in adults.

This enables the initiation of the EYETAC phase II clinical trial (NCT07285070) in patients with non-infectious anterior uveitis (NIAU).

The investigators evaluated the shear-stress-dependent viscous properties of seven commercially available tear formulations. They also studied the viscosity of natural tears.